U.S., Sept. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07191639) titled 'Description of the Impact of Symptoms on Quality of Life in HHT Disease: DISQUO' on Aug. 13.
Brief Summary: In 2017, the ELECT-RO study led, firstly, to the creation of a tool to measure quality of life (QoL) specific to HHT (hereditary haemorrhagic telangiectasia disease), QoL-HHT, based on patients' experiences, their representations and their difficulties. Secondly, the ELECT-RO study demonstrated the validity of the measurement scale, meaning that QoL-HHT does indeed measure patients' QoL and is therefore a reference tool.
QoL-HHT gives investigators a good understanding of the different aspects of patients' QoL (physical limi...